Sudewi Mukaromah Khoirunnisa

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 10

Top Topics

Sentinel Lymph Node

Epidermal Growth Factor Receptor

Metastatic Breast Cancer

Health Insurance

Top Venues

PharmacoEconomics - open

Expert review of pharmacoeconomics & outcomes research

This page only lists publications with an associated author ORCID identifier.

Publications

Sudewi Mukaromah Khoirunnisa, Fithria Dyah Ayu Suryanegara, Didik Setiawan, Maarten Jacobus Postma, Lisa Aniek de Jong
Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis. PloS one 19 (5) (2024)
Sudewi Mukaromah Khoirunnisa, Fithria Dyah Ayu Suryanegara, Lisa Aniek de Jong, Didik Setiawan, Maarten Jacobus Postma
A Systematic Review of Health-Related Quality of Life in Women with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab. PharmacoEconomics - open (2024)
Sudewi Mukaromah Khoirunnisa, Fithria Dyah Ayu Suryanegara, Didik Setiawan, Maarten Jacobus Postma
Quality-adjusted life years for HER2-positive, early-stage breast cancer using trastuzumab-containing regimens in the context of cost-effectiveness studies: a systematic review. Expert review of pharmacoeconomics & outcomes research 24 (5) (2024)
Sudewi Mukaromah Khoirunnisa, Fithria Dyah Ayu Suryanegara, Didik Setiawan, Maarten Jacobus Postma
Quality-adjusted life years for HER2-positive, early-stage breast cancer using trastuzumab-containing regimens in the context of cost-effectiveness studies: a systematic review. Expert review of pharmacoeconomics & outcomes research (2024)
Sudewi Mukaromah Khoirunnisa, Fithria Dyah Ayu Suryanegara, Didik Setiawan, Maarten Jacobus Postma, Lisa Aniek de Jong
Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis. PloS one 19 (5) (2024)
Sudewi Mukaromah Khoirunnisa, Fithria Dyah Ayu Suryanegara, Lisa Aniek de Jong, Didik Setiawan, Maarten Jacobus Postma
A Systematic Review of Health-Related Quality of Life in Women with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab. PharmacoEconomics - open 8 (4) (2024)
Sudewi Mukaromah Khoirunnisa, Fithria Dyah Ayu Suryanegara, Didik Setiawan, Maarten Jacobus Postma
Quality-adjusted life years for HER2-positive, early-stage breast cancer using trastuzumab-containing regimens in the context of cost-effectiveness studies: a systematic review. Expert review of pharmacoeconomics & outcomes research 24 (5) (2024)
Sudewi Mukaromah Khoirunnisa, Fithria Dyah Ayu Suryanegara, Didik Setiawan, Maarten Jacobus Postma
Quality-adjusted life years for HER2-positive, early-stage breast cancer using trastuzumab-containing regimens in the context of cost-effectiveness studies: a systematic review. Expert review of pharmacoeconomics & outcomes research (2024)
Sudewi Mukaromah Khoirunnisa, Fithria Dyah Ayu Suryanegara, Lisa Aniek de Jong, Didik Setiawan, Maarten Jacobus Postma
A Systematic Review of Health-Related Quality of Life in Women with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab. PharmacoEconomics - open 8 (4) (2024)
Sudewi Mukaromah Khoirunnisa, Fithria Dyah Ayu Suryanegara, Lisa Aniek de Jong, Didik Setiawan, Maarten Jacobus Postma
A Systematic Review of Health-Related Quality of Life in Women with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab. PharmacoEconomics - open 8 (4) (2024)